Jasper Therapeutics Inc (JSPR) is a pioneering biopharmaceutical company dedicated to advancing hematopoietic stem cell therapies aimed at improving treatment outcomes for patients suffering from severe conditions such as sickle cell disease and specific hematologic malignancies. Leveraging state-of-the-art technologies, Jasper seeks to minimize transplant-related complications, addressing critical unmet needs in the hematology and oncology fields. Supported by a robust intellectual property portfolio and strategic collaborations, the company is well-positioned to drive innovation and propel its clinical pipeline forward, underscoring its commitment to transformative solutions in regenerative medicine. Show more

P.O. BOX 10240, GEORGE TOWN, CAYMAN ISLANDS, KY1-1002, George Town, KY1-1002, USA

https://jaspertx.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

21.1M

52 Wk Range

$0.32 - $2.69

Previous Close

$0.58

Open

$0.59

Volume

303,561

Day Range

$0.59 - $0.66

Enterprise Value

12.3M

Cash

7.314M

Avg Qtr Burn

-6.919M

Insider Ownership

2.87%

Institutional Own.

39.43%

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Briquilimab (SC) Details Chronic spontaneous urticaria (CSU)	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vensobafusp Alfa (KP-104) (Dual Complement Inhibitor) Details Rare Renal Indications	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vensobafusp Alfa (KP-104) (Dual Complement Inhibitor) Details Paroxysmal Nocturnal Hemoglobinuria (PNH)	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Briquilimab (SC) Details Cold urticaria (ColdU) or symptomatic dermographism (SD)	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Briquilimab (SA SC) Details Asthma	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Briquilimab Details Severe combined immunodeficiency due to complete RAG1/2 deficiency	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.